As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) reduced the risk of disease progression or death versus ...
MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced detailed efficacy ...
Low-dose aspirin reduced colorectal cancer (CRC) recurrence rates by more than half in patients with tumors harboring mutations in the PI3K signaling pathway, according to findings from the phase 3 ...
Celcuity highlighted strong phase III second-line data for gedatolisib in PIK3CA "wild-type" HR-positive breast cancer — the triplet (gedatolisib + palbociclib + fulvestrant) showed median PFS of 9.3 ...
Hello, and thank you for standing by. My name is Bella, and I will be your conference operator today. At this time, I would like to welcome everyone to Phase III VIKTORIA-1 Additional Results ...
The tumor tissue-based real-time PCR kit will be used to identify patients with PIK3CA gene mutations eligible for treatment with PI3K inhibitor.
Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results